All content for Laboratory Considerations for Clinical Trials is the property of Q Squared Solutions and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This podcast from Q Squared Solutions looks at factors sponsors should consider when preparing for clinical trials.
In this episode, Drs. Steven Lowes and Barry Jones discuss hybrid assays, combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS). This is a growing area of opportunity for protein bioanalysis.
Topics covered include:
What is meant by hybrid assay
Reasons to choose a hybrid assay
Top down vs bottom up
Specific challenges
Assay design considerations
Future potential for this type of bioanalysis
...I think that fundamental point about more sensitivity, and associated with that is more selectivity, is going to be part of the future adoption of these hybrid assays. We have needs already, we can see needs for looking at quantifying proteins in very small samples, say tissue biopsies. - Steven Lowes
Learn more at Q2labsolutions.com.
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision (Article in Clinical Chemistry)
Laboratory Considerations for Clinical Trials
This podcast from Q Squared Solutions looks at factors sponsors should consider when preparing for clinical trials.
